International journal of biological macromolecules · 2025
Exosomal microRNA-20b-5p contributes to cytarabine resistance in acute myeloid leukemia via the microtubule-associated serine/threonine kinase-like-phosphatidylinositol 3-kinase-protein kinase B signaling axis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Aoshuang, Wang Li, Chen Ying, Zhao Zihao, Cheng Wei, Cheng WeiWei, Cheng Bingqing, Guo Hai, Li Ya, Cai Jiumei, Yang Jinghui, Zou Xue, Wang Jishi
Аннотация
BACKGROUND: Cytarabine (Ara-C) resistance limits durable remission in acute myeloid leukemia (AML). A working model posits that exosomal miR-20b-5p promotes resistance by repressing MASTL and sustaining PI3K-AKT signaling.
METHODS: Ara-C-resistant sublines were generated. Exosomes were purified and validated by TEM, NTA, and immunoblotting. Functional transfer used exosome-depleted serum with GW4869 and EV-depleted medium controls. MASTL targeting was tested with 3'-UTR dual-luciferase reporters and biotinylated-miRNA pull-down. Proteomics profiled pathways. Xenograft studies evaluated in vivo effects; MK-2206 probed AKT dependence.
RESULTS: Resistant-cell exosomes reduced Ara-C sensitivity of matched parental cells, and were enriched for miR-20b-5p; controls had no effect. Reporter and pull-down assays supported direct binding to the MASTL 3'-UTR, with reduced MASTL mRNA/protein and increased p-PI3K/p-AKT. Re-expression of MASTL lacking the 3'-UTR and AKT inhibition each partially reversed signaling and drug-response phenotypes. In relapsed blasts, a miRNA inhibitor restored MASTL and lowered p-PI3K. In vivo, leukemia-derived exosomes increased leukemic burden, consistent with an exosomal miR-20b-5p-MASTL-PI3K-AKT axis.
CONCLUSIONS: Exosomal miR-20b-5p represses MASTL, remodels PI3K-AKT, and attenuates Ara-C responses in AML models. Seed-mutant reporters and 3'-UTR-independent rescue support target specificity. Findings are mechanistic and hypothesis-generating; clinical relevance requires confirmation in primary blasts and prospective validation.
METHODS: Ara-C-resistant sublines were generated. Exosomes were purified and validated by TEM, NTA, and immunoblotting. Functional transfer used exosome-depleted serum with GW4869 and EV-depleted medium controls. MASTL targeting was tested with 3'-UTR dual-luciferase reporters and biotinylated-miRNA pull-down. Proteomics profiled pathways. Xenograft studies evaluated in vivo effects; MK-2206 probed AKT dependence.
RESULTS: Resistant-cell exosomes reduced Ara-C sensitivity of matched parental cells, and were enriched for miR-20b-5p; controls had no effect. Reporter and pull-down assays supported direct binding to the MASTL 3'-UTR, with reduced MASTL mRNA/protein and increased p-PI3K/p-AKT. Re-expression of MASTL lacking the 3'-UTR and AKT inhibition each partially reversed signaling and drug-response phenotypes. In relapsed blasts, a miRNA inhibitor restored MASTL and lowered p-PI3K. In vivo, leukemia-derived exosomes increased leukemic burden, consistent with an exosomal miR-20b-5p-MASTL-PI3K-AKT axis.
CONCLUSIONS: Exosomal miR-20b-5p represses MASTL, remodels PI3K-AKT, and attenuates Ara-C responses in AML models. Seed-mutant reporters and 3'-UTR-independent rescue support target specificity. Findings are mechanistic and hypothesis-generating; clinical relevance requires confirmation in primary blasts and prospective validation.